Sernova Biotherapeutics 

€0.09
0
+€0+2.72% Thursday 06:07

Statistics

Day High
0.09
Day Low
0.09
52W High
0.15
52W Low
0.08
Volume
-
Avg. Volume
-
Mkt Cap
31.45M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12JunExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.02
-0.02
-0.01
-0
Expected EPS
-0.006243986090999999
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-19.87MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PSH0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vericel
VCEL
Mkt Cap1.77B
Vericel Corporation specializes in cell therapies for markets similar to Sernova's, making them direct competitors in the regenerative medicine space.
Biolife Solutions
BLFS
Mkt Cap1.34B
BioLife Solutions provides bioproduction tools and services, including cell and gene therapy solutions, competing in the same support and supply chain as Sernova.
Mesoblast
MESO
Mkt Cap2.14B
Mesoblast Limited focuses on regenerative medicine, specifically in areas of inflammation and cardiovascular disease, overlapping with Sernova's therapeutic targets.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap6.74M
Brainstorm Cell Therapeutics develops adult stem cell therapies for neurodegenerative diseases, competing with Sernova's approach to chronic disease treatment through innovative therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is focused on gene editing, a cutting-edge area of medicine that competes indirectly with Sernova's cell therapy and regenerative medicine technologies.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing space, which represents a competitive alternative to Sernova's cell-based therapies for treating various diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the gene editing field, offering therapeutic solutions that could potentially rival Sernova's cell therapy approach.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, gene editing, and cell therapy, directly competing with Sernova's technology in multiple areas.

About

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
Show more...
CEO
ISIN
CA81752F1062
WKN
000A411DW

Listings

0 Comments

Share your thoughts

FAQ

What is Sernova Biotherapeutics stock price today?
The current price of PSH0.F is €0.09 EUR — it has increased by +2.72% in the past 24 hours. Watch Sernova Biotherapeutics stock price performance more closely on the chart.
What is Sernova Biotherapeutics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sernova Biotherapeutics stocks are traded under the ticker PSH0.F.
Is Sernova Biotherapeutics stock price growing?
PSH0.F stock has fallen by -2.07% compared to the previous week, the month change is a +11.18% rise, over the last year Sernova Biotherapeutics has showed a -25% decrease.
What is Sernova Biotherapeutics market cap?
Today Sernova Biotherapeutics has the market capitalization of 31.45M
When is the next Sernova Biotherapeutics earnings date?
Sernova Biotherapeutics is going to release the next earnings report on June 12, 2026.
What were Sernova Biotherapeutics earnings last quarter?
PSH0.F earnings for the last quarter are -0.01 EUR per share, whereas the estimation was -0.01 EUR resulting in a +0% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Sernova Biotherapeutics revenue for the last year?
Sernova Biotherapeutics revenue for the last year amounts to 0 EUR.
What is Sernova Biotherapeutics net income for the last year?
PSH0.F net income for the last year is -19.87M EUR.
When did Sernova Biotherapeutics complete a stock split?
Sernova Biotherapeutics has not had any recent stock splits.